Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
The links between oncogenic drivers and cancer cell metabolism have emerged over the past several decades, indicating that constitutive oncogenic growth signaling can render cancers susceptible to metabolic interventions. While significant progress has been achieved in identifying metabolic vulnerabilities of cancer cells, the complexity of the tumor microenvironment (TME) and the dynamic nature of organismal circadian metabolism challenge the precision of targeting cancer metabolism. Herein, current progress in the areas of cancer metabolism and TME metabolism is reviewed, highlighting how cancer metabolism can be accurately and precisely targeted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 9×
“Other tool compounds against LDHA, such as FX11, are effective in vivo, but have off-target effects at high concentrations and hence their antitumorigenic activity may not be due entirely to LDHA inhibition [47, 63].”
BackgroundInfluentialThe metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579 · cited 1×
“While engaging the mitochondria to catabolize nutrients is essential for the survival of cancer cells, the generation of byproducts can also be toxic and expose additional vulnerabilities such as the induction of autophagy by ammonia, the inhibition of NOS by nitric oxide, and oxidative stress generated by reactive ox…”
BackgroundOtto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Self-citationFundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · cited 3×
“Specifically, glycolysis is the most conserved pathway that converts glucose to pyruvate (Figure 1), which is further catabolized to lactate, alanine, alcohol, or transported into the mitochondrion depending on the metabolic wiring of the cell [5, 6].”
BackgroundCancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Self-citationGlutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Circadian integration of metabolism and energetics
Bass, J., & Takahashi, J. S. (2010) · Science · doi:10.1126/science.1195027 · Cited by 1,910 · cited 1×
“However, the normal stem cell cycle oscillator tends to couple with the circadian clock to orchestrate tissue repair and regeneration in synchrony with the solar cycle of fasting and feeding coupled with sleep and wake periods that are linked to cellular metabolism [81, 82].”
Background
Research works printed but not linked: 57
- Cantor, 2012, Cancer cell metabolism: one hallmark, many faces, Cancer Discov., 2, 881, 10.1158/2159-8290.CD-12-0345 · DOI · Paper page
- Buescher, 2015, A roadmap for interpreting 13C metabolite labeling patterns from cells, Curr. Opin. Biotechnol., 34, 189, 10.1016/j.copbio.2015.02.003 · DOI · Paper page
- Camarda, 2016, Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer, Nat. Med., 22, 427, 10.1038/nm.4055 · DOI · Paper page
- Huang, 2016, Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress, Cell Res., 26, 1112, 10.1038/cr.2016.109 · DOI · Paper page
- Pandey, 2017, The see-saw of Keap1–Nrf2 pathway in cancer, Crit. Rev. Oncol. Hematol., 116, 89, 10.1016/j.critrevonc.2017.02.006 · DOI
- Jaramillo, 2013, The emerging role of the Nrf2–Keap1 signaling pathway in cancer, Genes Dev., 27, 2179, 10.1101/gad.225680.113 · DOI · Paper page
- Viswanathan, 2017, Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway, Nature, 547, 453, 10.1038/nature23007 · DOI · Paper page
- Mucaj, 2012, Effects of hypoxia and HIFs on cancer metabolism, Int. J. Hematol., 95, 464, 10.1007/s12185-012-1070-5 · DOI
- Danhier, 2017, Cancer metabolism in space and time: beyond the Warburg effect, Biochim. Biophys. Acta, 1858, 556, 10.1016/j.bbabio.2017.02.001 · DOI · Paper page
- Maley, 2017, Classifying the evolutionary and ecological features of neoplasms, Nat. Rev. Cancer, 17, 605, 10.1038/nrc.2017.69 · DOI · Paper page
- Strickaert, 2017, Cancer heterogeneity is not compatible with one unique cancer cell metabolic map, Oncogene, 36, 2637, 10.1038/onc.2016.411 · DOI
- Nieman, 2011, Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth, Nat. Med., 17, 1498, 10.1038/nm.2492 · DOI · Paper page
- Wong, 2017, Endothelial cell metabolism in health and disease: impact of hypoxia, EMBO J., 36, 2187, 10.15252/embj.201696150 · DOI · Paper page
- De Bock, 2013, Role of PFKFB3-driven glycolysis in vessel sprouting, Cell, 154, 651, 10.1016/j.cell.2013.06.037 · DOI · Paper page
- Lee, 2015, A lactate-induced response to hypoxia, Cell, 161, 595, 10.1016/j.cell.2015.03.011 · DOI · Paper page
- Murray, 2015, Snapshot: immunometabolism, Cell Metab., 22, 10.1016/j.cmet.2015.06.014 · DOI
- O’Neill, 2016, A guide to immunometabolism for immunologists, Nat. Rev. Immunol., 16, 553, 10.1038/nri.2016.70 · DOI · Paper page
- Buck, 2017, Metabolic instruction of immunity, Cell, 169, 570, 10.1016/j.cell.2017.04.004 · DOI · Paper page
- Farber, 1949, Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer, Blood, 4, 160, 10.1182/blood.V4.2.160.160 · DOI · Paper page
- Landau, 1958, Animal responses to 2-deoxy-D-glucose administration, Proc. Soc. Exp. Biol. Med., 99, 124, 10.3181/00379727-99-24268 · DOI · Paper page
- Landau, 1958, Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose, J. Natl. Cancer Inst., 21, 485
- Doherty, 2014, Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis, Cancer Res., 74, 908, 10.1158/0008-5472.CAN-13-2034 · DOI · Paper page
- Chan, 2011, Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality, Sci. Transl. Med., 3, 94ra70, 10.1126/scitranslmed.3002394 · DOI · Paper page
- Le, 2010, Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression, Proc. Natl. Acad. Sci. U. S. A., 107, 2037, 10.1073/pnas.0914433107 · DOI · Paper page
- Schulze, 2012, How cancer metabolism is tuned for proliferation and vulnerable to disruption, Nature, 491, 364, 10.1038/nature11706 · DOI · Paper page
- Tennant, 2010, Targeting metabolic transformation for cancer therapy, Nat. Rev. Cancer, 10, 267, 10.1038/nrc2817 · DOI · Paper page
- Galluzzi, 2013, Metabolic targets for cancer therapy, Nat. Rev. Drug Discov., 12, 829, 10.1038/nrd4145 · DOI · Paper page
- Vander Heiden, 2011, Targeting cancer metabolism: a therapeutic window opens, Nat. Rev. Drug Discov., 10, 671, 10.1038/nrd3504 · DOI · Paper page
- Jones, 2012, Targeting cancer metabolism – aiming at a tumour’s sweet-spot, Drug Discov. Today, 17, 232, 10.1016/j.drudis.2011.12.017 · DOI · Paper page
- Noble, 2017, Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma, Haematologica, 102, 1247, 10.3324/haematol.2016.163030 · DOI · Paper page
- Doherty, 2013, Targeting lactate metabolism for cancer therapeutics, J. Clin. Invest., 123, 3685, 10.1172/JCI69741 · DOI · Paper page
- Marchiq, 2015, Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin, Cancer Res., 75, 171, 10.1158/0008-5472.CAN-14-2260 · DOI · Paper page
- Chen, 2016, Identification of a potent inhibitor targeting human lactate dehydrogenase A and its metabolic modulation for cancer cell line, Bioorg. Med. Chem. Lett., 26, 72, 10.1016/j.bmcl.2015.11.025 · DOI
- Ganapathy-Kanniappan, 2013, Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting, Anticancer Res., 33, 13
- Birsoy, 2013, MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors, Nat. Genet., 45, 104, 10.1038/ng.2471 · DOI · Paper page
- Cantor, 2017, Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase, Cell, 169, 258, 10.1016/j.cell.2017.03.023 · DOI · Paper page
- Tanaka, 2015, Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment, J. Clin. Invest., 125, 1591, 10.1172/JCI78239 · DOI · Paper page
- Lampa, 2017, Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition, PLoS One, 12, 10.1371/journal.pone.0185092 · DOI · Paper page
- Yuan, 2013, Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma, Proc. Natl. Acad. Sci. U. S. A., 110, 18226, 10.1073/pnas.1317577110 · DOI · Paper page
- Kim, 2017, Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma, J. Invest. Dermatol., 137, 1740, 10.1016/j.jid.2017.03.033 · DOI
- O’Neill, 2016, Immunometabolism governs dendritic cell and macrophage function, J. Exp. Med., 213, 15, 10.1084/jem.20151570 · DOI · Paper page
- He, 2017, CD155T/TIGIT signaling regulates CD8+ T cell metabolism and promotes tumor progression in human gastric cancer, Cancer Res., 77, 6375, 10.1158/0008-5472.CAN-17-0381 · DOI · Paper page
- Gentles, 2015, The prognostic landscape of genes and infiltrating immune cells across human cancers, Nat. Med., 21, 938, 10.1038/nm.3909 · DOI · Paper page
- Weger, 2017, Stem cells and the circadian clock, Dev. Biol., 431, 111, 10.1016/j.ydbio.2017.09.012 · DOI
- Bass, 2016, Circadian time signatures of fitness and disease, Science, 354, 994, 10.1126/science.aah4965 · DOI · Paper page
- Altman, 2017, Correspondence: Oncogenic MYC persistently upregulates the molecular clock component REV-ERBα, Nat. Commun., 8, 10.1038/ncomms14862 · DOI
- Altman, 2015, MYC disrupts the circadian clock and metabolism in cancer cells, Cell Metab., 22, 1009, 10.1016/j.cmet.2015.09.003 · DOI · Paper page
- Levi, 1997, Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy, Lancet, 350, 681, 10.1016/S0140-6736(97)03358-8 · DOI · Paper page
- Innominato, 2014, The circadian timing system in clinical oncology, Ann. Med., 46, 191, 10.3109/07853890.2014.916990 · DOI · Paper page
- Ballesta, 2017, Systems chronotherapeutics, Pharmacol. Rev., 69, 161, 10.1124/pr.116.013441 · DOI · Paper page
- Lin, 2016, Discovery of a novel 2,6-disubstituted glucosamine series of potent and selective hexokinase 2 inhibitors, ACS Med. Chem. Lett., 7, 217, 10.1021/acsmedchemlett.5b00214 · DOI
- Cui, 2016, Discovery of 2-((3-cyanopyridin-2-yl)thio)acetamides as human lactate dehydrogenase A inhibitors to reduce the growth of MG-63 osteosarcoma cells: virtual screening and biological validation, Bioorg. Med. Chem. Lett., 26, 3984, 10.1016/j.bmcl.2016.06.083 · DOI
- Billiard, 2013, Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells, Cancer Metab., 1, 19, 10.1186/2049-3002-1-19 · DOI · Paper page
- Rai, 2017, Discovery and optimization of potent, cell-active pyrazole-based inhibitors of lactate dehydrogenase (LDH), J. Med. Chem., 10.1021/acs.jmedchem.7b00941 · DOI · Paper page
- Ward, 2012, Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation, J. Med. Chem., 55, 3285, 10.1021/jm201734r · DOI · Paper page
- Alistar, 2017, Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, Phase 1 trial, Lancet Oncol., 18, 770, 10.1016/S1470-2045(17)30314-5 · DOI · Paper page
- Bose, 2017, Treatment of relapsed/refractory acute myeloid leukemia, Curr. Treat. Options Oncol., 18, 17, 10.1007/s11864-017-0456-2 · DOI · Paper page
Cited by
Targeting Ferroptosis as a Vulnerability in Cancer
Lei, G., Zhuang, L., & Gan, B. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00459-0 · Cited by 2,252
Lactate metabolism in human health and disease
Li, X., Yang, Y., Zhang, B., Lin, X., Fu, X., An, Y., Zou, Y., Wang, J.-X., Wang, Z., & Yu, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01151-3 · Cited by 1,454
Role of RNA modifications in cancer
Barbieri, I., & Kouzarides, T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0253-2 · Cited by 1,312
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Self-citationMutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
Liu, X., Olszewski, K., Zhang, Y., Lim, E. W., Shi, J., Zhang, X., Zhang, J., Lee, H., Koppula, P., Lei, G., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0496-x · Cited by 589
Sullivan, M. R., Danai, L. V., Lewis, C. A., Chan, S. H., Gui, D. Y., Kunchok, T., Dennstedt, E. A., Vander Heiden, M. G., & Muir, A. (2019) · eLife · doi:10.7554/elife.44235 · Cited by 588
“Numerous microenvironmental factors affect cancer cell metabolism (Anastasiou, 2017; Bi et al., 2018; Muir et al., 2018; Wolpaw and Dang, 2018), including the presence of stromal cells (Lyssiotis and Kimmelman, 2017; Morandi et al., 2016), tumor acidity (Corbet and Feron, 2017; Persi et al., 2018),…”
BackgroundBrown, T. P., & Ganapathy, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107451 · Cited by 481
iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4
Chen, D., Chu, B., Yang, X., Liu, Z., Jin, Y., Kon, N., Rabadan, R., Jiang, X., Stockwell, B. R., & Gu, W. (2021) · Nature Communications · doi:10.1038/s41467-021-23902-6 · Cited by 348
Immunometabolic Interplay in the Tumor Microenvironment
Kaymak, I., Williams, K. S., Cantor, J. R., & Jones, R. G. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.09.004 · Cited by 328
Tumor suppressor p53 and metabolism
Liu, J., Zhang, C., Hu, W., & Feng, Z. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy070 · Cited by 300
Ferroptosis Detection: From Approaches to Applications
Zeng, F., Nijiati, S., Tang, L., Ye, J., Zhou, Z., & Chen, X. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202300379 · Cited by 300
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151
Yamamoto, K., Brender, J. R., Seki, T., Kishimoto, S., Oshima, N., Choudhuri, R., Adler, S. S., Jagoda, E. M., Saito, K., Devasahayam, N., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-0928 · Cited by 37
Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics
Ferrari, A., Longo, R., Silva, R., Mitro, N., Caruso, D., De Fabiani, E., & Crestani, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.008 · Cited by 19
Metadata
- Authors
- Wolpaw, A. J., & Dang, C. V.
- Venue
- Trends in Cell Biology
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 28
- Issue
- 3
- Pages
- 201-212
- ISSN
- 0962-8924 (ISSN-L)
- OpenAlex
- W2774281839
- Cited by
- 146
- References
- 43
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- NCI (CA051497, CA057341)
- Ludwig Institute for Cancer Research
- Children’s Hospital of Philadelphia Department of Pediatrics training (5T32GM00736)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.